title: Inherited defects in the interferon-gamma receptor or interleukin-12 signalling pathways are not sufficient to cause allergic disease in children.
abstract: T-helper (Th)2 cells, which produce the cytokines interleukins (IL)-4, IL-5 and IL-13, dominate T cell responses in allergic diseases. The Th1-type cytokines IL-12 and interferon-gamma (IFNgamma) are important in down-regulating Th2 responses to allergens. Patients with defects in the IL-12 receptor (IL-12R) or IFNgamma receptor (IFNgammaR) have abnormal responses to IL-12 or IFNgamma and a failure to produce normal levels of IFNgamma. Current paradigms of T-helper subset balance would predict a high prevalence of atopic illness in this group. We have studied a cohort of patients (n =29) with defects in these pathways to assess the prevalence of allergic disease. A questionnaire based on those developed for the International Study of Asthma and Allergy in Childhood (ISAAC) was used in conjunction with analysis of total and specific IgE to common aeroallergens. The prevalence of asthma, eczema and rhino-conjunctivitis (13.7%, 17.5% and 6.8% respectively) in this group was no higher than in comparable populations where prevalences of 13.9%, 7.9% and 13.5% are reported for asthma, eczema and rhinoconjunctivitis respectively. Patients with IFNgammaR defects had higher rates of clinical atopic illness than control populations and patients with IL-12R defects, with 28.5% prevalences for asthma and eczema, respectively. None of the patients suffered from severe clinical atopic disease. Defects in interferon-gamma receptor/interleukin-12 receptor responses are not sufficient to cause clinical allergic disease. Patients with defects in the interferon-gamma receptor pathway have a higher prevalence of high IgE and clinical atopic illness compared to control populations, supporting the concept that interferon-gamma receptor signalling plays a role in down-regulating type-2 cytokine responses.
authors.affiliation: Department of Clinical Immunology and Allergy, St. James's University Hospital, Leeds, UK. Philip.wood@leedsth.nhs.uk
authors.forename: Philip M D
authors.initials: PM
authors.lastname: Wood
authors.forename: Claire
authors.initials: C
authors.lastname: Fieschi
authors.forename: Capucine
authors.initials: C
authors.lastname: Picard
authors.forename: Tom H M
authors.initials: TH
authors.lastname: Ottenhoff
authors.forename: Jean-Laurent
authors.initials: JL
authors.lastname: Casanova
authors.forename: Dinakantha S
authors.initials: DS
authors.lastname: Kumararatne
mesh_terms: D000293:Adolescent; D000328:Adult; D000485:Allergens / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology*; D007073:Immunoglobulin E / Q000097:blood; D007223:Infant; D008875:Middle Aged; D009154:Mutation; D017471:Receptors, Interferon / Q000235:genetics / Q000502:physiology*; D018123:Receptors, Interleukin / Q000235:genetics / Q000502:physiology*; D053707:Receptors, Interleukin-12; D015398:Signal Transduction; D018417:Th1 Cells; D000096743:Interferon gamma Receptor
chemical_list: D000485:Allergens; D007073:Immunoglobulin E; D017471:Receptors, Interferon; D018123:Receptors, Interleukin; D053707:Receptors, Interleukin-12; D000096743:Interferon gamma Receptor